---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-22-022077"
form_type: "8-K"
ticker: "LCTX"
cik: "0000876343"
company_name: "Lineage Cell Therapeutics, Inc."
filed_at: "2022-08-11T23:59:59+00:00"
generated_at: "2026-06-24T01:15:06.306839+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Lineage reports Q2 net loss of $6.8M ($0.04/sh); cash $72M supports through Q2 2024

## Summary
- Revenue $4.6M, up $4.0M YoY, primarily from Roche collaboration licensing fee.
- Net loss attributable to Lineage $6.8M ($0.04/sh) vs $4.8M ($0.03/sh) in Q2 2021.
- R&D expenses $3.3M; G&A $5.3M; total operating expenses $8.6M.
- Cash, equivalents, and marketable securities $72M; funds operations through Q2 2024.
- OpRegen collaboration with Roche advancing; OPC1 results published in J Neurosurg; VAC2 tech transfer complete.

## SEC filing metadata
- accession: 0001493152-22-022077
- form_type: 8-K
- ticker: LCTX
- cik: 0000876343
- company_name: Lineage Cell Therapeutics, Inc.
- filed_at: 2022-08-11T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/876343/000149315222022077/0001493152-22-022077-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/876343/000149315222022077/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-22-022077
- JSON: https://secwatch.observer/filing/0001493152-22-022077.json
- Plain text: https://secwatch.observer/filing/0001493152-22-022077.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.